PD-1 variant having improved binding ability to PD-L1
AssigneeElisigen Inc.
InventorsSang Taek Jung, Kwang-Jin Chun, Ji Yeon Ha
Life of this patent
Estimating the term…
Abstract
A PD-1 variant, which has improved binding affinity to PD-L1, and methods for preparing and screening the PD-1 variant. The PD-1 variant of the present disclosure effectively inhibits the binding between wild-type PD-1 and PD-L1, and thus is expected to have significantly higher penetration ability and anticancer effect by immune cells or therapeutic effect for infectious diseases as compared to existing immune checkpoint inhibitors. At the same time, the possibility of immunogenicity can be minimized. In addition, the convenience of developing biomedicine may be promoted through aglycosylation.
Claims14
An immune checkpoint inhibitor that inhibits binding between wild-type PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) consisting of a PD-1 variant having improved binding affinity to PD-L1 compared to wild-type PD-1, wherein the PD-1 variant is selected from the group consisting of the amino acid sequences set forth in SEQ ID NO:
- 52, SEQ ID NO:
- 53, and SEQ ID NO:
- 94.
An immune checkpoint inhibitor that inhibits binding between wild-type PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) comprising a PD-1 variant having improved binding affinity to PD-L1 compared to wild-type PD-1, wherein the PD-1 variant has the amino acid sequence of SEQ ID NO:
- 49, 52, 53, 91, 92, 93, or 94.
Dependencies are inferred from the claim text.